Abstract
We have identified a new series of C-5 substituted indazolylaminoquinazolines as potent erbB2 kinase inhibitors. The lead compound 22 showed excellent in vitro potency, good physical properties, acceptable oral pharmacokinetics in rat and dog, and low human in vitro clearance. It showed at least equivalent activity dose for dose compared to lapatinib in various erbB2- or EGFR-driven xenograft models after chronic oral administration.
MeSH terms
-
Administration, Oral
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / pharmacology*
-
Breast Neoplasms / drug therapy
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dogs
-
Epidermal Growth Factor / pharmacology
-
ErbB Receptors / antagonists & inhibitors*
-
Ether-A-Go-Go Potassium Channels
-
Female
-
Hepatocytes / cytology
-
Hepatocytes / drug effects
-
Hepatocytes / metabolism
-
Humans
-
Indazoles / chemical synthesis
-
Indazoles / pharmacology*
-
Keratinocytes / cytology
-
Keratinocytes / drug effects
-
Keratinocytes / metabolism
-
Lapatinib
-
Male
-
Metabolic Clearance Rate
-
Mice
-
Mice, Nude
-
Mice, SCID
-
Microsomes / drug effects
-
Molecular Structure
-
Neoplasms, Experimental / drug therapy*
-
Phosphorylation / drug effects
-
Protein Kinase Inhibitors / chemical synthesis
-
Protein Kinase Inhibitors / pharmacology*
-
Quinazolines / chemical synthesis
-
Quinazolines / pharmacology*
-
Rats
-
Rats, Wistar
-
Receptor, ErbB-2 / antagonists & inhibitors*
-
Survival Rate
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Ether-A-Go-Go Potassium Channels
-
Indazoles
-
KCNH1 protein, human
-
Protein Kinase Inhibitors
-
Quinazolines
-
Lapatinib
-
Epidermal Growth Factor
-
ErbB Receptors
-
Receptor, ErbB-2